Synthesis and biological evaluation of analogs of the marine alkaloids granulatimide and isogranulatimide.

[1]  G. Ferry,et al.  Characterization of novel checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors. , 2011, Life sciences.

[2]  R. Kiss,et al.  Considering temozolomide as a novel potential treatment for esophageal cancer , 2011, Cancer.

[3]  R. Kiss,et al.  In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. , 2011, Planta medica.

[4]  R. Kiss,et al.  Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells. , 2010, Journal of natural products.

[5]  S. Chassaing,et al.  Marine Pyrrolocarbazoles and Analogues: Synthesis and Kinase Inhibition , 2009, Marine drugs.

[6]  C. Pirker,et al.  The sodium pump α1 sub-unit: a disease progression–related target for metastatic melanoma treatment , 2009, Journal of cellular and molecular medicine.

[7]  S. Spiegl-Kreinecker,et al.  Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. , 2009, Journal of medicinal chemistry.

[8]  B. Hugon,et al.  Pyrrolocarbazoles as checkpoint 1 kinase inhibitors. , 2008, Anti-cancer agents in medicinal chemistry.

[9]  B. Ducommun,et al.  G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress , 2008, Oncogene.

[10]  C. Bailly,et al.  Synthesis and biological activities of isogranulatimide analogues. , 2007, Bioorganic & medicinal chemistry.

[11]  R. Kiss,et al.  The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. , 2007, Neoplasia.

[12]  Bernard Ducommun,et al.  CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.

[13]  L. Meijer,et al.  Purification of CK1 by affinity chromatography on immobilised axin. , 2007, Protein expression and purification.

[14]  R. Kiss,et al.  Can anti‐migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration , 2007, Medicinal research reviews.

[15]  R. Kiss,et al.  Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. , 2006, Neoplasia.

[16]  P. Plas,et al.  3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists. , 2005, Bioorganic & medicinal chemistry letters.

[17]  Baoguang Zhao,et al.  Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide. , 2004, Molecular cancer therapeutics.

[18]  C. McGowan,et al.  Running into problems: how cells cope with replicating damaged DNA. , 2003, Mutation research.

[19]  K. Vermeulen,et al.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer , 2003, Cell proliferation.

[20]  P. Renard,et al.  Synthesis of isogranulatimide analogues possessing a pyrrole moiety instead of an imidazole heterocycle , 2003 .

[21]  C. Heizmann,et al.  Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. , 2002, Biochimica et biophysica acta.

[22]  R. Kiss,et al.  Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy , 2002, Cancer.

[23]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[24]  F. Costantini,et al.  Purification of GSK-3 by affinity chromatography on immobilized axin. , 2000, Protein expression and purification.

[25]  R. Andersen,et al.  Improved synthesis of isogranulatimide, a G2 checkpoint inhibitor. Syntheses Of didemnimide C, isodidemnimide A, neodidemnimide A, 17-methylgranulatimide, and isogranulatimides A-C. , 2000, The Journal of organic chemistry.

[26]  T. Takeya,et al.  Total Synthesis of (.+-.)-Plumbazeylanone. , 1999 .

[27]  S. Haggarty,et al.  High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. , 1998, Cancer research.

[28]  R. Andersen,et al.  Granulatimide and Isogranulatimide, Aromatic Alkaloids with G2 Checkpoint Inhibition Activity Isolated from the Brazilian Ascidian Didemnum granulatum: Structure Elucidation and Synthesis† , 1998 .

[29]  T. Takeya,et al.  Total Synthesis of (±)-Plumbazeylanone , 1998 .

[30]  M. Faul,et al.  A New, Efficient Method for the Synthesis of Bisindolylmaleimides. , 1998, The Journal of organic chemistry.

[31]  T. Kurihara,et al.  A synthesis of arcyriacyanin A, an unsymmetrically substituted indole pigment of the slime mould by palladium catalyzed cross-coupling reaction , 1998 .

[32]  Reuben G. Jones,et al.  New Methods of Synthesis of β-Aminoethylpyrazoles , 1953 .

[33]  A. Cuddihy,et al.  Cell-cycle responses to DNA damage in G2. , 2003, International review of cytology.

[34]  M. Olivier,et al.  CELL CYCLE RESPONSES TO DNA DAMAGE IN P53 WT CANCER CELL LINES , 1996 .

[35]  V. Bocchi,et al.  High Yield Selective Bromination and Iodination of Indoles in N,N-Dimethylformamide , 1982 .